National Liver Institute
Shebeen Alkom, Monufia Governorate, 32511, Egypt
NCT Number: NCT02059460
To study the impact of intra and post-operative Terlipressin infusion on the occurrence of acute kidney injury after LDLT To investigate perioperative Neutrophil Gelatinase Associated Lipocalin (NGAL) changes and study the effect of Terlipressin on NGAL blood levels
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
Shebeen Alkom, Monufia Governorate, 32511, Egypt
The study will be conducted after approval of the local ethics and research committee of anesthesia, ICU and pain management of both Faculty of Medicine and Liver Institute, Menoufia University, Egypt. This study will be conducted in Anesthesia Department, National Liver Institute hospital on patients undergoing liver transplantation. They will be simply randomized with closed envelopes into two groups. Terlipressin group and Control group. A written informed consent will be taken from every patient.
Inclusion criteria
Adult living donor liver transplant recipients with no preoperative renal dysfunction Exclusion criteria: patients with renal insufficiency defined as serum creatinine > 2 mg/dl and GFR <60 ml/min by isotope scanning of the kidney.
Anesthetic Technique:
All patients will be monitored by electrocardiography, noninvasive and invasive arterial blood pressure, pulse oximetry, capnography, fraction inspired oxygen concentration (FiO2). After preoxygenation, general anesthesia will be induced with Propofol 2 mg/kg IV, Fentanyl 2 µg/kg IV and Rocronium 0.9 mg/kg IV followed by endotracheal intubation and maintenance with a mixture of air, oxygen 50% with Desflurane. Mechanical ventilation will be adjusted to maintain end-tidal CO2 between 35-40 mmHg. Central venous line will be inserted for monitoring of central venous pressure (CVP) with ultrasonography guidance.
The esophageal Doppler probe will then be inserted orally and positioned approximately 35-40 cm from the teeth (CardioQTM®, Deltex Medical, Chichester, UK). Normothermia (core temperature > 36°C) will be maintained intraoperatively using forced warming air blanket (Bair Hugger®; Arizant, UK).
After induction of anesthesia patients will be randomly divided into two groups Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively. In the control group, continuous placebo infusion will be started. The Anesthesia team will be kept blind to the contents of the infusion.
Rotetional thromboelastometry [ROTEM] will guide intraoperative blood transfusion protocol as prescribed by the study of Gorlinger K will be followed in both groups. (13) Platelets will be substituted when maximum clot firmness of (MCF EXTEM) <45mm and maximum clot firmness of FIBTEM (MCF FIBTEM) >8mm.
Fresh frozen plasma will be administerd when clot formation time representing extrinsic coagulation pathway (CFT EXTEM) was >240sec. Hematocrite will be kept more than or equal to 25 with packed red blood cells units.
All patients will receive intraoperative methylprednisolone (10 mg/kg). Hemodynamics will be maintained, keeping mean blood pressure above 60 mmHg by fluids and vasoactive drugs.
After surgery, all patients will be transferred to the intensive care unit for controlled mechanical ventilation. The patients will be extubated when hemodynamics are stable, liver graft functions satisfactory, sufficient spontaneous breathing, and core temperature >36°C.
Measured Parameters:
-Evaluation of renal function and injury:
Blood samples will be drawn at the predetermined time points and processed within 2 hours after collection. Serum will be collected and subsequently frozen at -80°Celsius until further analysis -Hemodynamic parameters:
Other parameters:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
Other names: Glypressin
Time frame: 5 days postoperatuvely
it is elevation of serum creatinine >1.5 mg/dL
National Liver Institute, Egypt
Other
Acronym: Terli-NGAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04008810
AKI, Acute Kidney Injury
Hillerød, Denmark
View Trial DetailsNCT06750770
Acute Kidney Injury, Female Urogenital Diseases
Beijing, Province, China
View Trial DetailsNCT06535945
Acute Kidney Injury, Female Urogenital Diseases
Chambray-lès-Tours, France
View Trial DetailsNCT06483139
Acute Kidney Injury, Blood Protein Disorders
Boston, Massachusetts, United States
View Trial Details